Fresenius Medical Care AG
Informe acción NYSE:FMS
Capitalización de mercado: US$12.5b
Fresenius Medical Care Crecimiento futuro
Future controles de criterios 2/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Fresenius Medical Care de 19.3% y 3.7% por año respectivamente. Se prevé que el BPA crezca en un 18% al año. Se espera que la rentabilidad financiera sea de 7.7% en 3 años.
Información clave
19.3%
Tasa de crecimiento de los beneficios
18.0%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Healthcare 20.9% Tasa de crecimiento de los ingresos 3.7% Rentabilidad financiera futura 7.7% Cobertura de analistas Good
Última actualización 06 Nov 2024
Actualizaciones recientes sobre el crecimiento futuro
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01
Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024 May 08 Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024 Feb 20
Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023
Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022 Aug 03
Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022 Jul 28
Mostrar todas las actualizaciones
Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025 Nov 05 Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025 Nov 01
Fresenius Medical Care: Let's Look At The Upside Oct 04 Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025 Aug 08
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01
Fresenius Medical Care: Significant Upside Remains Jun 25
Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024 May 08
Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device Mar 19 Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024 Mar 13
Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns Feb 23
Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023 Feb 21 Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024 Feb 20
Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S Feb 09
Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government Nov 23 Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023 Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024 Nov 07
An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME) Nov 03 Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024 Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery Nov 01
Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset Oct 27
Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off Oct 12
Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software Aug 24 An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).
Fresenius Medical Care Announces Executive Changes Jul 11
Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates Jun 21
Fresenius Medical Care: Other Stocks Still Better, But Upside Exists Jun 01
Fresenius Medical Care Q4 2022 Earnings Preview Feb 21
Fresenius: The Company Is Climbing, And I'm At 'Buy' Jan 06 Fresenius Medical Care AG & Co. KGaA Announces CEO Changes Dec 06
Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023 Nov 16 Fresenius Medical Care AG & Co. KGaA to Report Q2, 2023 Results on Aug 02, 2023
Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis) Oct 27
Fresenius Medical gains after report of activist Elliott stake in Fresenius SE Oct 19
Fresenius cut to Hold at Jefferies citing staffing issues and inflation Oct 10
Fresenius gets award to provide dialysis services to U.S. military veterans Aug 30
Fresenius appoints head of pharma unit as new CEO Aug 19
Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022 Aug 03
Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat Jul 30
Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022 Jul 28
Fresenius Medical Care accused of Medicare fraud in dialysis Jul 13
Fresenius Medical Care AG & Co. KGaA to Report Q3, 2022 Final Results on Nov 09, 2022 May 15
Fresenius: The Upside Is Getting Bigger May 02
Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office Apr 06
Fresenius Medical Care AG & Co. KGaA Proposes Dividend, Due on 17 May 2022 Apr 01 Fresenius Medical Care Ag & Co. Kgaa Provides Earnings Forecast for the Year 2022
Fresenius Medical Care Reportedly in Talks to Buy Dmed Diyaliz Jan 27
Fresenius Medical Care AG & Co. KGaA Launches New Mobile App to Empower and Engage Nurses Dec 21
You Really Want To Know About Fresenius Medical Care Aug 28
Fresenius Medical Care Approves Dividend for the Fiscal Year 2020 May 21
Fresenius Medical Care Confirms Earnings Guidance for the Fiscal Year 2021 May 07
Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2020 Final Results on Mar 23, 2021 Mar 17
Fresenius Medical Care AG & Co. KGaA to Report Q3, 2021 Results on Nov 02, 2021 Feb 24
Fresenius Medical drops 12% on disappointing 2021 outlook Feb 02
Fresenius Medical Care's Frenova Enrolls Patients in Initiative to Build Large Genomic Registry Targeting Kidney Disease Jan 12 Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 20, 2021
Fresenius Medical Care EPS beats by €0.06, misses on revenue Oct 29
Fresenius Medical Care AG & Co. KGaA to Report Q1, 2020 Results on May 06, 2020 Sep 30
Fresenius Medical Care AG & Co. KGaA to Report Q2, 2020 Results on Jul 30, 2020 Sep 22
Previsiones de crecimiento de beneficios e ingresos NYSE:FMS - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 20,630 1,102 1,878 2,713 16 12/31/2025 19,870 936 1,956 2,562 18 12/31/2024 19,258 676 1,783 2,572 18 9/30/2024 19,239 659 1,538 2,274 N/A 6/30/2024 19,415 530 1,342 2,049 N/A 3/31/2024 19,474 484 1,911 2,613 N/A 12/31/2023 19,454 499 1,918 2,629 N/A 9/30/2023 19,463 450 1,799 2,509 N/A 6/30/2023 19,622 596 1,674 2,407 N/A 3/31/2023 19,554 602 1,401 2,152 N/A 12/31/2022 19,398 673 1,397 2,167 N/A 9/30/2022 19,048 763 1,444 2,237 N/A 6/30/2022 18,393 806 1,444 2,271 N/A 3/31/2022 17,957 878 1,576 2,441 N/A 12/31/2021 17,619 969 1,603 2,489 N/A 9/30/2021 17,372 918 1,477 2,405 N/A 6/30/2021 17,344 998 1,480 2,459 N/A 3/31/2021 17,581 1,131 2,869 3,857 N/A 12/31/2020 17,859 1,164 3,148 4,233 N/A 9/30/2020 18,039 1,330 3,299 4,420 N/A 6/30/2020 18,044 1,309 3,377 4,542 N/A 3/31/2020 17,832 1,212 1,832 3,075 N/A 12/31/2019 17,477 1,200 1,404 2,567 N/A 9/30/2019 17,196 1,282 1,367 2,494 N/A 6/30/2019 16,835 1,234 1,246 2,379 N/A 3/31/2019 16,704 1,974 1,065 2,182 N/A 12/31/2018 16,547 1,982 920 2,062 N/A 9/30/2018 16,676 1,951 766 1,892 N/A 6/30/2018 16,954 1,975 N/A 1,750 N/A 3/31/2018 17,211 1,250 N/A 1,977 N/A 12/31/2017 17,784 1,280 N/A 2,192 N/A 9/30/2017 17,771 1,249 N/A 2,436 N/A 6/30/2017 17,647 1,244 N/A 2,217 N/A 3/31/2017 17,201 1,239 N/A 1,938 N/A 12/31/2016 16,570 1,144 N/A 1,932 N/A 9/30/2016 16,101 1,063 N/A 1,648 N/A 6/30/2016 15,841 998 N/A 1,782 N/A 3/31/2016 15,402 933 N/A 1,491 N/A 12/31/2015 15,455 955 N/A 1,767 N/A 9/30/2015 15,345 939 N/A 1,791 N/A 6/30/2015 15,246 948 N/A 1,914 N/A 3/31/2015 15,428 977 N/A 2,044 N/A 12/31/2014 13,329 864 N/A 1,538 N/A 9/30/2014 12,413 839 N/A 1,476 N/A 6/30/2014 11,112 775 N/A 1,283 N/A 3/31/2014 10,882 791 N/A 1,329 N/A 12/31/2013 10,816 806 N/A 1,478 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.3% al año) de FMS es superior a la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Se prevé que los beneficios (19.3% al año) de FMS crezcan más rápidamente que el mercado US (15.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de FMS crezcan, pero no significativamente .
Ingresos vs. Mercado: Se prevé que los ingresos (3.7% al año) de FMS crezcan más despacio que el mercado de US (8.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 3.7% al año) de FMS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de FMS sea baja dentro de 3 años (7.7%).
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}